Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals reports positive Phase 2 Data for ISIS-FXI Rx


Thursday, 22 May 2014 07:00am EDT 

Isis Pharmaceuticals Inc:Says positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXIRxundergoing total knee replacement surgery, or total knee arthroplasty (TKA). 

Company Quote

63.65
4.16 +6.99%
26 Dec 2014